A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to find the highest tolerable dose of AMV564 that can be given to patients with acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has stopped responding to treatment). The safety of AMV564 will also be studied. This is the first study using AMV564 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: AMV564
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Amphivena Therapeutics, Inc.
IRB Review and Approval Date: 06/21/2017
Recruitment Status: Open
Projected Accrual: 124
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: